Cyclosporine Or Derivative Utilizing Patents (Class 514/20.5)
  • Publication number: 20140094418
    Abstract: The present invention is directed to palatable ductile chewable veterinary composition for oral administration. The composition is capable of killing endo-parasites and ecto-parasites and/or can be used for treating prophylactic or curative animal diseases, and it is useful for the treatment of any warm-blooded non-human animal, including herd animals, like horses, cattle, sheep or poultry and preferably pets like dogs and cats. It consists basically of (A) an effective amount of one or more ingredients that are active against animal pests, pathogens or animal diseases; (B) meat flavoring; (C) partially gelatinized starch; (D) a softener; and (E) up to 9% water.
    Type: Application
    Filed: December 11, 2013
    Publication date: April 3, 2014
    Applicant: NOVARTIS AG
    Inventor: Ute Isele
  • Patent number: 8685930
    Abstract: Methods of treating an eye of a human or animal include administering to an eye of a human or animal a composition in the form of an emulsion including water, a hydrophobic component and a cyclosporin component in a therapeutically effective amount of less than 0.1% by weight of the composition. The weight ratio of the cyclosporin component to the hydrophobic component is less than 0.8.
    Type: Grant
    Filed: August 7, 2013
    Date of Patent: April 1, 2014
    Assignee: Allergan, Inc.
    Inventors: Andrew Acheampong, Diane D. Tang-Liu, James N. Chang, David F. Power
  • Publication number: 20140057854
    Abstract: Provided herein include formulations for topical administration, such as ophthalmic formulations, and methods of using such formulations. In some aspects and embodiments the formulations may include a polyoxyl lipid or fatty acid, and or a polyalkoxylated alcohol and may include nanomicelles. Also include methods of treating or preventing diseases or conditions, such as ocular diseases or conditions.
    Type: Application
    Filed: August 23, 2013
    Publication date: February 27, 2014
    Inventors: Ashim K. Mitra, Sidney L. Weiss
  • Publication number: 20140057855
    Abstract: A composition comprising from about 0.001% to about 0.4% cyclosporin A, a surfactant, and an oil having a specific gravity from 0.8 to 0.95 is disclosed herein.
    Type: Application
    Filed: November 4, 2013
    Publication date: February 27, 2014
    Applicant: ALLERGAN, INC.
    Inventors: James N. Chang, Orest Olejnik, Bruce A. Firestone
  • Publication number: 20140050728
    Abstract: Methods and compositions for modulating cyclophilin D, e.g., at least one cyclophilin D biological activity, are provided. Modulation of cyclophilin D is useful in preventing or treating obesity, an overweight condition, or in accommodating a desire to lose weight as well as being useful in treating a variety of kidney diseases.
    Type: Application
    Filed: January 27, 2012
    Publication date: February 20, 2014
    Applicant: BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA
    Inventor: Babu Padanilam
  • Publication number: 20140045772
    Abstract: A composition is disclosed herein comprising from about 0.001% to about 0.
    Type: Application
    Filed: October 21, 2013
    Publication date: February 13, 2014
    Applicant: ALLERGAN, INC.
    Inventors: James N. Chang, Orest Olejnik, Bruce A. Firestone
  • Publication number: 20140044689
    Abstract: The disclosure generally describes methods of preventing or treating ophthalmic diseases or conditions in a mammalian subject, such as diabetic retinopathy, cataracts, retinitis pigmentosa, glaucoma, macular degeneration, choroidal neovascularization, retinal degeneration, and oxygen-induced retinopathy. The methods comprise administering an effective amount of an aromatic-cationic peptide to subjects in need thereof.
    Type: Application
    Filed: May 17, 2013
    Publication date: February 13, 2014
    Inventors: Liping LIU, Shibo TANG, Xiaoling LIANG
  • Publication number: 20140044779
    Abstract: A fluid carrier comprises first and second substantially immiscible liquids. The first liquid is an open-chain silicone oil of the formula [(CH3)3Si—O]—[(CH2)2Si—O]n—[Si(CH3)3]. The second liquid is a polar lipid material. The first and second liquids are capable of forming an unstable dispersion. The unstable dispersion can be stabilized by adding a powderous solid insoluble in the liquids. The powderous solid is selected from pharmacologically active agent, pharmaceutical excipient, and their mixtures. The stabilized dispersion is of a creamy or ointment-like or mouldable form, and can be filled into capsules or moulded into tablets so as to be fit for peroral administration.
    Type: Application
    Filed: April 20, 2012
    Publication date: February 13, 2014
    Applicant: LIPIDOR AB
    Inventors: Anders Carlsson, Bengt Herslöf, Jan Holmbäck
  • Patent number: 8648048
    Abstract: Methods of treating an eye of a human or animal include administering to an eye of a human or animal a composition in the form of an emulsion including water, a hydrophobic component and a cyclosporin component in a therapeutically effective amount of less than 0.1% by weight of the composition. The weight ratio of the cyclosporin component to the hydrophobic component is less than 0.8.
    Type: Grant
    Filed: August 14, 2013
    Date of Patent: February 11, 2014
    Assignee: Allergan, Inc.
    Inventors: Andrew Acheampong, Diane D. Tang-Liu, James N. Chang, David F. Power
  • Publication number: 20140038905
    Abstract: Therapeutic methods are disclosed herein.
    Type: Application
    Filed: August 2, 2013
    Publication date: February 6, 2014
    Inventors: Gregg Feinerman, Neil Barth, Rhett Schiffman, Pamela S. Barnett
  • Publication number: 20140038904
    Abstract: Therapeutic methods are disclosed herein.
    Type: Application
    Filed: August 2, 2013
    Publication date: February 6, 2014
    Inventors: Gregg Feinerman, Neil Barth, Rhett Schiffman, Pamela S. Barnett
  • Patent number: 8642556
    Abstract: Methods of treating an eye of a human or animal include administering to an eye of a human or animal a composition in the form of an emulsion including water, a hydrophobic component and a cyclosporin component in a therapeutically effective amount of less than 0.1% by weight of the composition. The weight ratio of the cyclosporin component to the hydrophobic component is less than 0.8.
    Type: Grant
    Filed: August 14, 2013
    Date of Patent: February 4, 2014
    Assignee: Allergan, Inc.
    Inventors: Andrew Acheampong, Diane D. Tang-Liu, James N. Chang, David F. Power
  • Publication number: 20140030340
    Abstract: A method for preparing poorly water soluble drug particles is disclosed. The method comprises dissolving a drug in at least one organic solvent to form a drug/organic mixture, spraying the drug/organic mixture into an aqueous solution and concurrently evaporating the organic solvent in the presence of the aqueous solution to form an aqueous dispersion of the drug particles. The resulting drug particles are in the nanometer to micrometer size range and show enhanced dissolution rates and reduced crystallinity when compared to the unprocessed drug. The present invention additionally contemplates products and processes for new drug formulations of insoluble drug particles having high dissolution rates and extremely high drug-to-excipient ratios.
    Type: Application
    Filed: October 3, 2013
    Publication date: January 30, 2014
    Applicant: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: Keith P. Johnston, Robert O. Williams, III, Xiaoxia Chen
  • Publication number: 20140031298
    Abstract: Compositions, and methods of using such compositions, useful for injection into the posterior segments of human or animal eyes are provided. Such compositions include small particles of a poorly soluble therapeutic agent that facilitates formation of concentrated regions of the therapeutic agent in the retinal pigmented epithelium of an eye. The particles are formed by combining a therapeutic agent with an ophthalmically acceptable polymer component. The particles have sizes less than about 3000 nanometers, and in some cases, less than about 200 nanometers. One example of a composition includes particles of triamcinolone acetonide and hyaluronic acid have a size less than about 3000 nanometers.
    Type: Application
    Filed: April 5, 2013
    Publication date: January 30, 2014
    Applicant: Allergan, Inc.
    Inventors: Patrick M. Hughes, Orest Olejnik, Scott M. Whitcup, James A. Burke
  • Publication number: 20140030226
    Abstract: Therapeutic methods are disclosed herein.
    Type: Application
    Filed: August 2, 2013
    Publication date: January 30, 2014
    Inventors: Gregg Feinerman, Neil Barth, Rhett Schiffman, Pamela S. Barnett
  • Publication number: 20140023614
    Abstract: The present invention relates to substituted fused tricyclic compounds of formula (I) or (Ia), their tautomers, polymorphs, stereoisomers, prodrugs, solvates, co-crystals, pharmaceutically acceptable salts, pharmaceutical compositions containing them and methods of treating conditions and diseases that are mediated by JAK activity. The compounds of the present invention are useful in the treatment, prevention or suppression of diseases and disorders mediated by JAK activity.
    Type: Application
    Filed: March 21, 2012
    Publication date: January 23, 2014
    Inventors: Dinesh Barawkar, Tanushree Bende, Robert Zahler, Anish Bandyopadhyay, Robindro Singh Sarangthem, Jignesh Doshi, Yogesh Waman, Rushikesh Jadhav, Umesh Prasad Singh
  • Publication number: 20140024587
    Abstract: A method for treating hair loss in mammals uses compositions containing prostaglandin F analogs. The compositions can be applied topically to the skin. The compositions can arrest hair loss, reverse hair loss, and promote hair growth.
    Type: Application
    Filed: September 23, 2013
    Publication date: January 23, 2014
    Applicant: Duke University
    Inventors: Mitchell A. deLong, John M. McIver, Robert S. Youngquist
  • Patent number: 8633162
    Abstract: Methods of treating an eye of a human or animal include administering to an eye of a human or animal a composition in the form of an emulsion including water, a hydrophobic component and a cyclosporin component in a therapeutically effective amount of less than 0.1 % by weight of the composition. The weight ratio of the cyclosporin component to the hydrophobic component is less than 0.8.
    Type: Grant
    Filed: August 14, 2013
    Date of Patent: January 21, 2014
    Assignee: Allergan, Inc.
    Inventors: Andrew Acheampong, Diane D. Tang-Liu, James N. Chang, David F. Power
  • Patent number: 8629111
    Abstract: Methods of treating an eye of a human or animal include administering to an eye of a human or animal a composition in the form of an emulsion including water, a hydrophobic component and a cyclosporin component in a therapeutically effective amount of less than 0.1% by weight of the composition. The weight ratio of the cyclosporin component to the hydrophobic component is less than 0.8.
    Type: Grant
    Filed: August 14, 2013
    Date of Patent: January 14, 2014
    Assignee: Allergan, Inc.
    Inventors: Andrew Acheampong, Diane D. Tang-Liu, James N. Chang, David F. Power
  • Publication number: 20140011750
    Abstract: Therapeutic methods are disclosed herein.
    Type: Application
    Filed: August 2, 2013
    Publication date: January 9, 2014
    Inventors: Gregg Feinerman, Neil Barth, Rhett Schiffman, Pamela S. Barnett
  • Publication number: 20140011753
    Abstract: A composition comprising a therapeutically effective amount of cyclosporin A, a blend of oils having a specific gravity of from 0.90 to 1.07, and a surfactant is disclosed herein.
    Type: Application
    Filed: September 13, 2013
    Publication date: January 9, 2014
    Applicant: ALLERGAN, INC.
    Inventors: James N. Chang, Orest Olejnik, Bruce A. Firestone
  • Publication number: 20140010949
    Abstract: Coatings for medical devices, methods of making the coatings, and methods of using them are described.
    Type: Application
    Filed: July 16, 2013
    Publication date: January 9, 2014
    Inventors: Keith M. Faucher, Hui Tang, Lisa Rogers, Joseph Ferraro, Paul Martakos, Steven A. Herweck, Theodore Karwoski
  • Publication number: 20140011752
    Abstract: Therapeutic methods are disclosed herein.
    Type: Application
    Filed: August 14, 2013
    Publication date: January 9, 2014
    Applicant: Allergan, Inc.
    Inventors: Gregg Feinerman, Neil Barth, Rhett Schiffman, Pamela S. Barnett
  • Publication number: 20140011751
    Abstract: Therapeutic methods are disclosed herein.
    Type: Application
    Filed: August 14, 2013
    Publication date: January 9, 2014
    Inventors: Gregg Feinerman, Neil Barth, Rhett Schiffman, Pamela S. Barnett
  • Publication number: 20140010821
    Abstract: The present invention relates to improved methods of suppressing and/or preventing an undesired immune response comprising the use of CD83. In some embodiments, CD83 is coadministered to a subject with at least one other immunosuppressive compound. Methods are also provided for generating tolerogenic dendritic cells and regulatory T cells. These cells can be used in vitro to produce additional cells for therapeutic purposes or they can be used in vivo to suppress and/or prevent an undesired immune response. Methods of the invention can be used to prevent or reduce the severity of autoimmune diseases and can also be used to induce tolerance to at least one therapeutic composition, such as a therapeutic protein or transplanted tissue.
    Type: Application
    Filed: August 16, 2007
    Publication date: January 9, 2014
    Inventor: Aili Lao
  • Publication number: 20140005100
    Abstract: The present invention relates to a compound of the formula (I), (II), (III), (IV), (V), or (VI) or pharmaceutically acceptable salt thereof, wherein the symbols are as defined in the specification; a pharmaceutical composition comprising the same, a method for treating or preventing a viral infection using the same.
    Type: Application
    Filed: August 12, 2011
    Publication date: January 2, 2014
    Inventors: Zhuang Su, Zhengyu Long, Zhennian Huang, Suizhou Yang
  • Publication number: 20140005123
    Abstract: The invention provides lipid-based pharmaceutical compositions comprising alisporivir.
    Type: Application
    Filed: December 12, 2011
    Publication date: January 2, 2014
    Applicants: DEBIOPHARM S.A., NOVARTIS AG
    Inventors: Elisabete Goncalves, Karin Rapp, Bertrand Sutter, Frank Stowasser, Bjoern Trupp, Sebastian Chabaut, Julien Thorens
  • Publication number: 20140005124
    Abstract: The present invention provides a method for the treatment of inflammatory diseases and/or conditions, e.g. allergic conjunctivitis, uveitis or phacoanaphylactic endophthalmitis in an eye of a mammal, said method comprising administering to said mammal in need of treatment a therapeutically effective amount of a novel cyclosporin A derivative selected from the group consisting of compounds represented by the formula: wherein R1 is S-Alk-R wherein Alk is an alkylene linkage, preferably a methylene or poly methylene linkage, or a polyalkenylene linkage, e.g. a C3 to C6 alkenylenyl linkage and R is a hydrogen or a unsubstituted or substituted hydrocarbyl group.
    Type: Application
    Filed: August 30, 2013
    Publication date: January 2, 2014
    Applicant: Allergan, Inc.
    Inventors: Michael E. Garst, Michael E. Stern
  • Patent number: 8618064
    Abstract: Methods of treating an eye of a human or animal include administering to an eye of a human or animal a composition in the form of an emulsion including water, a hydrophobic component and a cyclosporin component in a therapeutically effective amount of less than 0.1% by weight of the composition. The weight ratio of the cyclosporin component to the hydrophobic component is less than 0.8.
    Type: Grant
    Filed: August 28, 2007
    Date of Patent: December 31, 2013
    Assignee: Allergan, Inc.
    Inventors: Andrew Acheampong, Diane Tang-Liu, James N. Chang, David F. Power
  • Patent number: 8618065
    Abstract: A cyclosporin derivative of general Formula (I) or a pharmaceutically compatible salt thereof, which have a pharmaceutical effectiveness, for example in the case of chronic inflammatory diseases. The cyclosporin derivatives are preferably free from a peptide section capable of passing through the membrane of a biological cell.
    Type: Grant
    Filed: February 15, 2012
    Date of Patent: December 31, 2013
    Assignee: Max-Planck-Gesellschaft zur Foerderung der Wissenschaften E.V.
    Inventors: Gunter Fischer, Miroslav Malesevic, Frank Erdmann, Jan Kühling, Michael Bukrinsky, Stephanie Constant
  • Publication number: 20130345149
    Abstract: Compositions, products and methods including silicone based excipients are provided. The compositions, products and methods of the present invention are particularly useful for the treatment of ophthalmic diseases.
    Type: Application
    Filed: August 21, 2013
    Publication date: December 26, 2013
    Applicant: ALLERGAN, INC.
    Inventors: Kevin S. Warner, Ajay Parashar
  • Publication number: 20130345148
    Abstract: Therapeutic methods are disclosed herein.
    Type: Application
    Filed: August 14, 2013
    Publication date: December 26, 2013
    Inventors: Gregg Feinerman, Neil Barth, Rhett Schiffman, Pamela S. Barnett
  • Publication number: 20130345147
    Abstract: Therapeutic methods are disclosed herein.
    Type: Application
    Filed: August 2, 2013
    Publication date: December 26, 2013
    Inventors: Gregg Feinerman, Neil Barth, Rhett Schiffman, Pamela S. Barnett
  • Publication number: 20130344066
    Abstract: There is a need for improved methods for determining the diagnosis and prognosis of patients with conditions, including autoimmune disease and cancer. Provided herein are methods for using DNA sequencing to identify personalized biomarkers in patients with autoimmune disease and other conditions. Identified biomarkers can be used to determine the disease state for a subject with an autoimmune disease or other condition.
    Type: Application
    Filed: May 30, 2013
    Publication date: December 26, 2013
    Applicant: Sequenta, Inc.
    Inventors: Malek Faham, Thomas Willis
  • Publication number: 20130345150
    Abstract: An ophthalmic composition comprising a polyaphron dispersion.
    Type: Application
    Filed: March 14, 2012
    Publication date: December 26, 2013
    Inventor: Fraser Steele
  • Publication number: 20130338083
    Abstract: Methods of treating an eye of a human or animal include administering to an eye of a human or animal a composition in the form of an emulsion including water, a hydrophobic component and a cyclosporin component in a therapeutically effective amount of less than 0.1% by weight of the composition. The weight ratio of the cyclosporin component to the hydrophobic component is less than 0.8.
    Type: Application
    Filed: August 14, 2013
    Publication date: December 19, 2013
    Applicant: Allergan, Inc.
    Inventors: Andrew Acheampong, Diane D. Tang-Liu, James N. Chang, David F. Power
  • Publication number: 20130337019
    Abstract: Compositions containing quaternary compounds in which the nitrogen atom is substituted by at least one alkyl group having at least 12 carbon atoms, and the composition includes at least 20% in weight by weight of the total composition, of ammonium halides in which the nitrogen atom is substituted by at least one alkyl group having at least 14 carbon atoms and more than 5%, preferably more than 7% in weight by weight of the total composition, of ammonium halides in which the nitrogen atom is substituted by at least one alkyl group having at least 16 carbon atoms. Also, ophthalmic oil-in-water emulsions containing such compositions, the ophthalmic emulsions being useful for eye care or for the treatment of eye conditions.
    Type: Application
    Filed: August 2, 2013
    Publication date: December 19, 2013
    Applicant: NOVAGALI PHARMA SA
    Inventors: LAURA RABINOVICH-GUILATT, GREGORY LAMBERT, FREDERIC LALLEMAND, BETTY PHILIPS
  • Publication number: 20130338082
    Abstract: Methods of treating an eye of a human or animal include administering to an eye of a human or animal a composition in the form of an emulsion including water, a hydrophobic component and a cyclosporin component in a therapeutically effective amount of less than 0.1% by weight of the composition. The weight ratio of the cyclosporin component to the hydrophobic component is less than 0.8.
    Type: Application
    Filed: August 7, 2013
    Publication date: December 19, 2013
    Applicant: Allergan, Inc.
    Inventors: Andrew Acheampong, Diane D. Tang-Liu, James N. Chang, David F. Power
  • Publication number: 20130331340
    Abstract: Methods of treating an eye of a human or animal include administering to an eye of a human or animal a composition in the form of an emulsion including water, a hydrophobic component and a cyclosporin component in a therapeutically effective amount of less than 0.1% by weight of the composition. The weight ratio of the cyclosporin component to the hydrophobic component is less than 0.8.
    Type: Application
    Filed: August 14, 2013
    Publication date: December 12, 2013
    Applicant: Alllergan, Inc.
    Inventors: Andrew Acheampong, Diane D. Tang-Liu, James N. Chang, David F. Power
  • Publication number: 20130331336
    Abstract: Methods of treating an eye of a human or animal include administering to an eye of a human or animal a composition in the form of an emulsion including water, a hydrophobic component and a cyclosporin component in a therapeutically effective amount of less than 0.1% by weight of the composition. The weight ratio of the cyclosporin component to the hydrophobic component is less than 0.8.
    Type: Application
    Filed: August 7, 2013
    Publication date: December 12, 2013
    Applicant: Allergan, Inc.
    Inventors: Andrew Acheampong, Diane D. Tang-Liu, James N. Chang, David F. Power
  • Publication number: 20130330411
    Abstract: An oral cyclosporin composition comprises minicapsules having a core containing a cyclosporin, especially cyclosporin A in a solubilised liquid form. The minicapsules have a release profile to release the pre-solubilised cyclosporin, at least in the colon. The composition may be used for treating a range of intestinal diseases [FIG. 10].
    Type: Application
    Filed: July 15, 2013
    Publication date: December 12, 2013
    Inventor: Ivan Coulter
  • Publication number: 20130331338
    Abstract: Methods of treating an eye of a human or animal include administering to an eye of a human or animal a composition in the form of an emulsion including water, a hydrophobic component and a cyclosporin component in a therapeutically effective amount of less than 0.1% by weight of the composition. The weight ratio of the cyclosporin component to the hydrophobic component is less than 0.8.
    Type: Application
    Filed: August 7, 2013
    Publication date: December 12, 2013
    Applicant: Allergan, Inc.
    Inventors: Andrew Acheampong, Diane D. Tang-Liu, James N. Chang, David F. Power
  • Publication number: 20130331337
    Abstract: Methods of treating an eye of a human or animal include administering to an eye of a human or animal a composition in the form of an emulsion including water, a hydrophobic component and a cyclosporin component in a therapeutically effective amount of less than 0.1% by weight of the composition. The weight ratio of the cyclosporin component to the hydrophobic component is less than 0.8.
    Type: Application
    Filed: August 7, 2013
    Publication date: December 12, 2013
    Applicant: Allergan, Inc.
    Inventors: Andrew Acheampong, Diane D. Tang-Liu, James N. Chang, David F. Power
  • Publication number: 20130331339
    Abstract: Methods of treating an eye of a human or animal include administering to an eye of a human or animal a composition in the form of an emulsion including water, a hydrophobic component and a cyclosporin component in a therapeutically effective amount of less than 0.1% by weight of the composition. The weight ratio of the cyclosporin component to the hydrophobic component is less than 0.8.
    Type: Application
    Filed: August 14, 2013
    Publication date: December 12, 2013
    Applicant: Allergan, Inc.
    Inventors: Andrew Acheampong, Diane D. Tang-Liu, James N. Chang, David F. Power
  • Publication number: 20130331341
    Abstract: Methods of treating an eye of a human or animal include administering to an eye of a human or animal a composition in the form of an emulsion including water, a hydrophobic component and a cyclosporin component in a therapeutically effective amount of less than 0.1% by weight of the composition. The weight ratio of the cyclosporin component to the hydrophobic component is less than 0.8.
    Type: Application
    Filed: August 14, 2013
    Publication date: December 12, 2013
    Applicant: Allergan, Inc.
    Inventors: Andrew Acheampong, Diane D. Tang-Liu, James N. Chang, David F. Power
  • Publication number: 20130323295
    Abstract: Provided are compositions containing engineered particles, and methods of making such engineered particles. Polymeric articles, such as contact lenses, prepared from such compositions are also provided. Such engineered particles are dispersible in hydrophilic systems such as monomer systems for preparation of contact lenses. Each of the engineered particles comprises a hydrophobic core and a hydrophilic shell. The hydrophobic core comprises a silicone-based polymer that can have multiple cross-links and/or polymer-polymer entanglement, and the hydrophilic shell is formed from a reactive stabilizer. A residue of the reactive stabilizer or a hydrophilic segment of the reactive stabilizer can form the shell. The particles have an average particle size of less than about 500 nm.
    Type: Application
    Filed: November 20, 2012
    Publication date: December 5, 2013
    Applicant: Johnson & Johnson Vision Care, Inc.
    Inventor: Johnson & Johnson Vision Care, Inc.
  • Publication number: 20130323270
    Abstract: The present invention relates to a cyclosporine emulsion containing: i) a cyclosporine ii) a natural oil (long chain triglyceride) iii) a phosphatidylcholine, iv) glycerol, v) a pharmaceutically tolerable alkali salt of a free fatty acid, vi) a medium chain triglyceride-oil vii) optionally, hydrochloric acid or sodium hydroxide for pH adjustment viii) water.
    Type: Application
    Filed: September 30, 2011
    Publication date: December 5, 2013
    Applicant: NeuroVive Pharmaceutical AB
    Inventor: Eskil Elmér
  • Publication number: 20130324480
    Abstract: The present invention relates to novel cyclosporin analogs, processes for preparing them, pharmaceutical compositions containing them, and methods for using these analogs and the compositions containing them for the treatment of medical conditions, including but not limited to ocular conditions such as dry eye.
    Type: Application
    Filed: May 30, 2013
    Publication date: December 5, 2013
    Inventors: Simon N. Pettit, Andrew D. Jones, Catherine Simone V. Frydrych, William R. Carling, Michael E. Garst
  • Publication number: 20130324481
    Abstract: This invention provides for biocompatible, biodegradable eye drop pharmaceutical formulations useful for the treatment of ocular indications. In particular, tocopherols and their esters of low water solubility, notably ?-tocopheryl acetate, are exceptional vehicles for biocompatible, nonirritating topical eye drop formulations that provide sustained release of active agents.
    Type: Application
    Filed: August 9, 2013
    Publication date: December 5, 2013
    Applicant: Ramscor, Inc.
    Inventors: Vernon G. Wong, Louis L. Wood
  • Publication number: 20130316961
    Abstract: The invention relates to the use of cystamine, cysteamine, or a salt thereof, or of calcineurin inhibitors for treating a MeCP2-associated disorder such as Rett syndrome.
    Type: Application
    Filed: October 24, 2011
    Publication date: November 28, 2013
    Applicants: UNIVERSITÉ D'AIX-MARSEILLE, INSTITUT CURIE, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, INSERM (Institut National de la Santé et de la Recherche Médicale)
    Inventors: Jean-Christophe Roux, Laurent Villard, Frédéric Saudou